David Rosmarin
Co-Chair · Indiana University School of Medicine
Credentials: · · · ·
History
- Present
Dermatology Department · Indiana University School of Medicine
- 2009–2010
- 2005–2006
Preliminary or Transitional Year
Research
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
New England Journal of Medicine · 2022 · First of 15 authors · 220 citations
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
The Lancet · 2020 · First of 12 authors · Corresponding · 208 citations
Review · Journal of the American Academy of Dermatology · 2007 · Last of 3 authors · 200 citations
19 papers
- JH
18 papers
17 papers
15 papers
13 papers
12 papers
12 papers
- PG
12 papers
Clinical trials
- 2020–2022
Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab
Principal investigator · Completed · Phase 2
Tufts Medical Center
- 2020–2022
Topical Crisaborole in Patients with Alopecia Areata
Principal investigator · Withdrawn · Phase 2
Tufts Medical Center
- 2017–2020
Principal investigator · Terminated · Early phase 1
Tufts Medical Center
- 2016–2017
Topical Ruxolitinib for the Treatment of Vitiligo
Principal investigator · Completed · Phase 2
Tufts Medical Center